Integrative multi-omics, machine learning, and experimental validation reveal that TPM1 suppresses M2 macrophage polarization and enhances chemosensitivity in acute myeloid leukemia.
Source check: Source checked. Not independent scientific confirmation.
Finding: ML feature selection across AML transcriptomic/proteomic datasets prioritized TPM1; cell-line perturbations and a xenograft model then showed TPM1-linked AML growth, Ara-C sensitivity, and M2 macrophage effects. MeRIP/RIP, reporter, and mRNA-stability assays support an FTO/m6A mechanism destabilizing TPM1. This is preclinical evidence, not clinical efficacy.
Technology: LASSO, SVM-RFE and random-forest analyses of AML transcriptomic/proteomic datasets selected TPM1 as a candidate, which was then experimentally perturbed.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- LASSO, SVM-RFE and random-forest analyses of AML transcriptomic/proteomic datasets selected TPM1 as a candidate, which was then experimentally perturbed.
- Test and result
- TPM1 overexpression reduced AML cell growth, increased apoptosis/oxidative stress and Ara-C sensitivity, and attenuated M2 polarization; mechanistic assays support FTO-dependent m6A-mediated TPM1 mRNA destabilization.
- Limitation / still unknown
- Follow-up includes AML cell-line perturbations, macrophage co-culture, MeRIP/RIP and mRNA-stability assays, and xenograft groups of six mice; evidence remains preclinical.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13424268/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.